Expedeon (now part of Abcam)
Biotechnology ResearchEngland, United Kingdom1001-5000 Employees
We are now part of Abcam and will shortly be closing this account. Follow Abcam for the latest news and information. See you there!
Innovation and Product Launches Abcam has been actively expanding its product portfolio, exemplified by the launch of multiplex detection immunoassay kits in 2023, indicating ongoing investment in innovative solutions for biomarker detection, which could present opportunities for advanced reagent and assay partnerships.
Leadership Changes Recent leadership appointments, such as the appointment of Markus Lusser as president in March 2024, suggest strategic shifts and potential new focus areas, offering a chance to align sales efforts with evolving corporate priorities and decision-makers.
Market Positioning As part of Abcam, a globally recognized player in biotech research tools, Expedeon benefits from strong industry positioning, enabling sales strategies targeting companies seeking reliable biotech reagents, research tools, and custom solutions.
Operational Restructuring The closure of US offices in California and staff redundancies in 2023 reflect ongoing operational restructuring, providing potential entry points for supply chain enhancement solutions or integrative service offerings to support organizational efficiency.
Financial Profile With a modest revenue range up to 1 million dollars and recent funding of 6.5 million dollars, the company presents opportunities for tailored financial or partnership solutions to support growth initiatives and product development efforts in a competitive biotech landscape.
Expedeon (now part of Abcam) uses 8 technology products and services including Google AdWords, Grafana, Docker, and more. Explore Expedeon (now part of Abcam)'s tech stack below.
| Expedeon (now part of Abcam) Email Formats | Percentage |
| First.Last@expedeon.com | 73% |
| Last@expedeon.com | 18% |
| First@expedeon.com | 9% |
| First.Last@abcam.com | 88% |
| FLast@abcam.com | 11% |
| First.L@abcam.com | 1% |
Biotechnology ResearchEngland, United Kingdom1001-5000 Employees
We are now part of Abcam and will shortly be closing this account. Follow Abcam for the latest news and information. See you there!
Expedeon (now part of Abcam) has raised a total of $6.5M of funding over 2 rounds. Their latest funding round was raised on Aug 30, 2018 in the amount of $6.5M.
Expedeon (now part of Abcam)'s revenue is estimated to be in the range of $1M
Expedeon (now part of Abcam) has raised a total of $6.5M of funding over 2 rounds. Their latest funding round was raised on Aug 30, 2018 in the amount of $6.5M.
Expedeon (now part of Abcam)'s revenue is estimated to be in the range of $1M